Addex Therapeutics
ADXN
10 hedge funds and large institutions have $1.21M invested in Addex Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
100% more funds holding
Funds holding: 5 → 10 (+5)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2% more capital invested
Capital invested by funds: $1.19M → $1.21M (+$22.7K)
0.37% more ownership
Funds ownership: 0.1% → 0.47% (+0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$5.27M |
| 2 |
AC
Armistice Capital
New York
|
+$74.9K |
| 3 |
Renaissance Technologies
New York
|
+$33K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$25.2K |
| 5 |
Millennium Management
New York
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$36K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.03K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $830K | +$5.27M | +235,363 | +500% |
|
|
AC
2
Armistice Capital
New York
| $256K | +$74.9K | +3,349 | +26% |
|
|
NLVP
3
New Leaf Venture Partners
New York
| $40K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $24K | +$33K | +1,477 | New |
|
|
FIA
5
FNY Investment Advisers
New York
| $17K | +$25.2K | +1,125 | New |
|
|
6
Millennium Management
New York
| $16K | +$22.3K | +998 | New |
|
|
TSS
7
Two Sigma Securities
New York
| $10K | +$13.5K | +604 | New |
|
8
Citadel Advisors
Miami,
Florida
| $10K | +$14.3K | +640 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $6K | -$1.03K | -46 | -12% |
|
|
OMC
10
Old Mission Capital
Chicago,
Illinois
| – | -$36K | -1,557 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | +$134 | +6 | New |
|
ADXN Hedge Fund Activity: Q3 2022 in Review
10 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q3 2022, worth a combined $1.21M — up 1.9% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ADXN positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was NEA Management Company, adding an estimated $5.27M. The largest seller was Old Mission Capital, exiting entirely with an estimated $36K sold.
- 10 institutional investors held Addex Therapeutics (ADXN) as of Q3 2022, up from 5 in Q2 2022.
- Funds reported $1.21M of Addex Therapeutics stock for Q3 2022, up 1.9% quarter-over-quarter.
- 6 funds opened new Addex Therapeutics positions in Q3 2022 and 1 closed out, a net change of +5 holders.
- The largest Addex Therapeutics buyer in Q3 2022 was NEA Management Company, an estimated $5.27M added.
- The largest Addex Therapeutics seller in Q3 2022 was Old Mission Capital, an estimated $36K sold.
Based on aggregated 13F filings for Q3 2022.